Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60,892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH. Pietzak EJ, et al. Among authors: li q. Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3. Eur Urol. 2017. PMID: 28583311 Free PMC article.
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin D, Rosenberg JE, D'Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW. Li Q, et al. Clin Cancer Res. 2019 Feb 1;25(3):977-988. doi: 10.1158/1078-0432.CCR-18-1001. Epub 2018 Jul 6. Clin Cancer Res. 2019. PMID: 29980530 Free PMC article.
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G. Pietzak EJ, et al. Among authors: li q. Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2. Eur Urol. 2019. PMID: 30290956 Free PMC article.
Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
Gopalakrishnan D, Elsayed AS, Hussein AA, Jing Z, Li Q, Wagner AA, Aboumohamed A, Roupret M, Balbay D, Wijburg C, Stockle M, Dasgupta P, Khan MS, Wiklund P, Hosseini A, Peabody J, Shigemura K, Trump D, Guru KA, Chatta G. Gopalakrishnan D, et al. Among authors: li q. Int J Urol. 2022 Mar;29(3):197-205. doi: 10.1111/iju.14749. Epub 2021 Dec 19. Int J Urol. 2022. PMID: 34923677
Relapses Rates and Patterns for Pathological T0 After Robot-Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium.
Elsayed AS, Iqbal U, Jing Z, Houenstein HA, Wijburg C, Wiklund P, Kim E, Stöckle M, Kelly J, Dasgupta P, Wagner AA, Kaouk J, Badani KK, Redorta JP, Mottrie A, Peabody JO, Rouprêt M, Balbay D, Richstone L, Rha KH, Aboumohamed A, Li Q, Hussein AA, Guru KA. Elsayed AS, et al. Among authors: li q. Urology. 2022 Aug;166:177-181. doi: 10.1016/j.urology.2022.03.035. Epub 2022 Apr 21. Urology. 2022. PMID: 35461914
60,892 results
You have reached the last available page of results. Please see the User Guide for more information.